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   On the importance of intellectual 
property rights for e-science and the 
integrated health record 
Giuseppina D’Agostino, Chris Hinds, Marina Jirotka, 
Charles Meyer, Tina Piper, Mustafizur Rahman and David Vaver 
 
An integrated health record (IHR) that enables clinical data to be 
shared at a national level has profound implications for medical research. 
Data that have been useful primarily within a single clinic will instead 
be free to move rapidly around a national network infrastructure. This 
raises challenges for technologists, clinical practice, and for the 
governance of these data. This article considers one specific issue that is 
currently poorly understood: how intellectual property (IP) relates to the 
sharing of medical data for research on large-scale electronic networks. 
Based on an understanding of current practices, this article presents 
recommendations for the governance of IP in an integrated health record. 
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The notion that the introduction of new healthcare technologies may 
necessitate legal clarification is not new. Norris [1], for example, has 
considered the legal challenges presented by information management 
technologies in general, and more specifically telemedicine [2] and, with 
Galpottage, e-consent systems [3]. These studies each highlight the need for the 
law, and our understandings of it, to evolve in parallel with technologies and the 
practices that surround them. The complex relationship between medical data, 
medical practice, and the law has also been the subject of much previous 
 
 
research; see for example Lederman’s [4] study of data protection in large 
hospitals. This article is also concerned with medical data, specifically with the 
intellectual  property  rights  (IPRs)  in data, and how they may be particularly 
relevant to secondary uses of those data. 
Our investigations were motivated by a desire to examine these issues 
as they have emerged in real cases, and thus we orient our discussion in this article 
around a particular case study.1 The eDiaMoND (Digital Mammography National 
Database) [5] project aimed to develop a federated database of digital  
mammographic  images  and  patient-related data underpinned by grid technology. 
The database was created to support breast cancer screening and research 
nationally. This 2 year interdisciplinary flagship UK e-science project involved a core of 
30–50 staff spread over 12 locations, including five universities, four NHS trusts, a 
global computer firm, and a rapidly expanding university spin-out enterprise. The 
project received extensive public interest, including articles published by Wired 
and the BBC, and even a press statement by Prime Minister Tony Blair. The issues 
discussed and elaborated in this article are derived from a detailed analysis of this 
project. Key members of the eDiaMoND team were interviewed within the relevant 
academic, clinical and commercial organizations including managers, researchers, 
clinicians, and software developers. Project documents were gathered and reviewed 
to  provide  an  overview  of what happened within the project. Contracts were also 
obtained detailing the legal arrangements and provided a basis for focused legal 
analysis. 
The sharing of patient data is critical to medical research. An essential part of  
 
 
our research has been to understand the  practices  that  currently  surround  
secondary uses of medical data. [e.g. 6] Current  practices  highlight  how  a  level  of  
trust,  often based on long-term  research  relationships,  has  allowed  health  
services  and  universities to share data and engage in mutually beneficial 
collaborations [7]. In addition, collaborations with  commercial  organizations  are  of  
critical  importance  to  medical  research.  It is quite normal for these collaborations 
to involve some benefit for the health service department involved such as the 
provision of state-of-the-art equipment or technical support from the commercial 
partner. In both situations, medical data are a vital resource that may be employed 
to  ensure  maximum  benefit  for  the  health  service.  However, and perhaps 
unsurprisingly, the ways in which these arrangements are orchestrated are often 
ad hoc and made on a local basis. 
The e-science vision of seamless global sharing of data for research [8] 
and recent UK NHS initiatives present specific challenges to these current localized 
arrangements. These innovations raise complex questions relating to ownership 
and control of the data, and, once ethical obligations have been satisfied, the 
exploitation of the data for profit. Answers to such questions require invoking IP. A 
lack of clarity on these issues may potentially lead either to a complete 
unwillingness to share data, or conversely to costly litigation when conflicting 
claims come to light; neither is a desirable outcome. 
The eDiaMoND project focused on the application of grid technologies 
within the UK NHS Breast Screening Programme. Central to this vision was an 
expected shift from film-based to digital mammography technologies. Once 
 
 
mammograms were in digital form, it was anticipated that a database would be 
required to store and manage them. eDiaMoND sought to develop such a 
database on a national level, and then apply grid technology to manage a series of 
services to utilize those data. The grid has many potential benefits for digital 
mammography: radiologists will be able to share images and expertise 
in new ways; new grid-enabled computer aided decision algorithms may 
be developed and used to assist in the reading process; and epidemiologists will 
be able to draw upon vast stores of accumulated image data for the first time in 
their cancer research. In order to demonstrate the eDiaMoND vision, it was 
necessary to obtain a significant quantity of patient data from the clinics 
collaborating on the project. However, setting up the agreements that led to the 
acquisition of these data was far from straightforward. In most cases the clinics 
were keen to participate and willingly contributed data. Nonetheless, one of the 
clinics requested explicit contractual terms before their data would be 
released. The negotiations between this clinic, their corresponding partner 
university, and the coordinating institution, Oxford, took over a year to settle 
and hence significantly delayed the project’s data collection effort. IP rights were 
of primary concern in these negotiations, and a significant source of confusion. 
As one team member put it, ‘We initially said to [our] lawyers, “Who owns the 
data?”, and they never came back with an answer!’ [9]. Thus, the eDiaMoND 
project is of significant interest, not only because it was considered to be a high-





Intellectual property and the value of medical data 
The issue of concern for the clinicians who requested explicit contractual 
terms before their data would be released was the potential commercial 
exploitation of the data they were asked to provide. eDiaMoND was a collaboration 
that consisted of a number of commercial partners, and it was perceived that some 
of the technologies that they contributed to the project were very close to being 
products with commercial value. In addition, these clinicians had for a number of 
years, and through collaboration with their local university, been involved in 
developing a multimedia tool for the training of radiologists, a key application of the 
eDiaMoND project (references withheld). The clinicians had provided a substantial 
corpus of images that formed the basis of the training tool and a number of 
promising prototypes had already been developed. Becoming a part of the 
eDiaMoND consortium raised the possibility of substantial benefits as the tool 
could now be connected to a vast national database of images. However, giving 
the data to this consortium raised the possibility that the clinic might lose 
control over them. In particular, the clinics perceived a risk that their data might 
become part of a commercial training tool that they might then later on be obliged 
to buy. For the clinicians, the prospect of buying a digital copy of what they 
perceived to be ‘their’ data was not acceptable. Such examples provide strong 
indications of the ways in which clinicians perceive the value for others of the data 




Though the case study chosen for this article revolves around an e-
science initiative, the issue of IP governance is nevertheless of concern to the 
use of medical data in a wider context. At the time of the project’s inception, 
the technical grid infrastructure of eDiaMoND was considered innovative, but 
the notion of building databases for medical research is, of course, far from 
new. The General Practice Research Database (GPRD) is an excellent example. 
Originally started in 1987, it is now the world’s largest computerized database 
of anonymized longitudinal patient records from general practice, holding 
data from practices throughout the UK and representing approximately 5 per cent 
of its population [10]. The size of the database along with the aggregated nature of 
the data, and the online access that researchers are granted, clearly resonates with 
the aspirations of the case study presented in this article. Although now 
managed by the Medicines Control Agency as a not-for-profit operation [11], the 
project initially started as a commercial enterprise. In its former incarnation as the 
privately funded Value Added Medical Products (VAMP) Research Database, GPs 
were offered free computer systems and instruction in exchange for high-quality 
anonymized patient prescription data. It was a deal that attracted over 2000 
general practitioners [12] and further highlights the perceived commercial value of 
medical data. 
More recently, the Icelandic parliament has passed a bill allowing deCODE, 
a predominantly American funded private company, to obtain a comprehensive 
electronic database containing health information about the country’s entire 
population, and link this to both genetic and genealogical information [13]. One 
 
 
objection to this controversial initiative related to the company’s ability to sign 
exclusive deals with pharmaceutical companies that might prevent other scientists 
from accessing the data. The deCODE example further reflects both the value that 
medical data may hold for a range of potential users, and the importance of its 
governance for research. 
IP is an important legal tool for controlling and protecting medical data. 
In addition, understanding how IP in medical data may be governed is important not 
just for eDiaMoND research as it moves toward initiating follow-on projects, but also 
for healthcare research more generally. For example, the CLEF project [14] is seeking 
to develop a generic framework for research using medical data. In common with 
the early approach of eDiaMoND, research has not yet begun to address the issue of 
how IP in the data their systems handle may be governed. The eDiaMOND may be 
particularly relevant as the CLEF researchers seek industrial partners to continue the 
development of their  platform  and  begin  to deploy professional tools to clinical 
and academic researchers and the pharmaceuticals industry [15]. 
On a much grander scale, eDiaMoND foreshadows current projects 
within the NHS, including Connecting for Health (CfH) in England, which seek both 
to computerize medical services and to link them at a national level [16]. Within 
CfH, the initiative of greatest interest, given the topic of this article, is perhaps the 
Secondary Uses Service (SUS). Whilst initial releases of the SUS focus on providing 
information for healthcare management such as the Payment by Results (PbR) 
scheme, future versions are intended to facilitate a kind of medical research that 
resonates strongly with the e-science vision, giving researchers access to healthcare 
 
 
data of an unprecedented range, breadth, and depth. It is widely recognized that 
good governance of data will be critical to the success of the SUS. However, recent 
consultations indicate that, at the present time, questions remain, particularly with 
respect to allowing non-NHS organizations to access the database and determining 
ways in which this access should be governed [17]. 
The following section details the main legal issues that were identified as 
relevant and consequential to our understanding of IP in the eDiaMoND project. 
Once the main issues in law have been described, we then detail the ways in which 
such laws may apply to the specific practices that shaped the eDiaMoND 
collaborations. From this analysis, we produce some specific recommendations as to 




It is perhaps not surprising that, by and large, many researchers, 
participants in projects and the public at large are unfamiliar with the ways in 
which IP relates to medical data [18]. Issues relating to IP rights over data and 
databases and control over data are complex and often decided on precedent. 
Throughout the course of our investigations, it became clear that there was a 
fundamental lack of understanding and in some cases misunderstanding by non-
specialists of IP law, and of law more generally. In many cases, academics, 
researchers, engineers and administrators did not fully  appreciate  that  medical  
data could even be subject to IP, much less that there may be various ways in 
 
 
which this might occur. In addition, there was a recurring perception that IP was 
obstructive to research, something that we needed to ‘get rid of’ rather than a 
means of protecting individuals and organizations. These perceptions sit in sharp 
contrast to the reality that IP cannot be eliminated unless explicitly assigned or 
effectively ‘donated’ to the public. 
The following sections summarize the most relevant legal concerns to 
the questions that emerged from the eDiaMoND case study. The main legal 
issues examined were copyright, database and other rights in the mammograms 
(MMRs) and in the software. Whilst we recognized the importance and interplay of 
ethical, confidentiality, data access and privacy concerns, we do not directly address 
these issues here. The interaction between all these factors is extremely complex 
and this project starts to unravel this complexity by focusing explicitly on IP 
ownership questions in the UK. On these issues, other jurisdictions have been 
consulted for comparative purposes.2 
 
Copyright law 
A key objective of copyright is to grant exploitation rights to owners of 
original works. Thus, under the UK Copyright, Designs and Patents Act 1988 
(CDPA),3 copyright initially grants various enumerated exploitation rights to the 
‘author’ who ‘creates’ a work.4 That work must meet the legal standard of 
‘originality’.5 The test for a work’s originality is a matter of degree depending on 
the amount of skill, judgement, or labour involved in its making.6 Consequently, 
not only must creative intellectual activity produce the right kind of work, but ‘the 
 
 
author’s input must satisfy a certain minimum standard of effort’ .7 The author is an 
individual who is solely responsible and exclusively deserving of the credit for the 
creation of a work.8 The CDPA grants protection to a number of categories of 
works. For instance, a literary work is defined in the CDPA as a written work, other 
than dramatic or musical, that may include computer programs or compilations. 
 
Determining copyright ownership 
The first owner of copyright is typically the creator, but there are 
exceptions. One of the main exceptions particularly relevant to the eDiaMoND 
case study deals with employees. Whilst independent contractors retain copyright 
over their works (unless an express or implied contract provides otherwise), 
employees’ copyright ownership of their works resides with their employers pursuant 
to the ‘course of employment’ doctrine.9 Contract law governs the management of 
copyrights. In the UK, the CDPA governs copyright transfers and licences. A 
licence may be express, oral or implied by conduct and may be exclusive or 
nonexclusive. Similar in scope to assignments,10 exclusive licences must be in writing 
authorizing the licensee to exercise a right to the exclusion of all other persons 
including the licensor.11 Non-exclusive licences imply that other licensees may be 
appointed to compete with one another and the independent contractor.12 It also 
means that, in contrast to assignments that transfer ownership, the independent 
contractors retain the right to exclude everyone other than the licensees from use of 
their works.13 Licences can be limited by time, scope, use and duration. Assignments 
and licences can be partial. For example, independent contractors may license only 
 
 
print rights. In the UK, future copyright can be assigned,14 thereby vesting 
copyright in the assignee once the future work comes into existence. Moral rights can 
be waived in writing but cannot be assigned.15 So if independent contractors 
intend to grant assignments or exclusive licences, these must be in writing. 
 
Database law 
European databases are governed by a complex legal regime. The EC 
Database Directive16 provides the most comprehensive legal protection of 
databases. Its provisions have been implemented and modified in the UK by the 
Database Regulations.17 Two other legal instruments also apply to databases: the 
UK Copyright, Designs and Patents Act in s. 3A, and Article 5 of the World 
Intellectual Property Organization (WIPO) Copyright Treaty. The Database Directive 
and UK Regulations most directly apply to the eDiaMoND database. 
There are three tiers of substantive legal protection of databases in IP law: 
(1) the database itself is protected by copyright; (2) the investment in databases is 
guarded by the database right; and (3) the contents of the database may be 
protected by copyright or other IPRs (such as patents, trademarks etc.). This last 
ground was discussed above; the first two will be addressed in turn. 
The UK Regulations define a database as ‘a collection of independent 
works, data or other materials which (a) are arranged in a systematic or methodical 
way, and (b) are individually accessible by electronic or other means’.18 The 
Explanatory Memorandum describes the contents of the database as “information” 
in the widest sense of that term’ and this definition of a database has recently 
 
 
been explored by the European Court of Justice.19 
The creator of a database is also protected against unauthorized 
extraction or utilization from the database by the so-called sui generis data-base 
right in the Database Directive. Its protections have been imported and modified in 
UK law by the UK Database Regulations and were recently extensively addressed by 
the European Court of Justice.20 
The database right belongs to the person who takes the initiative and 
assumes the risk in investing in obtaining, verifying or presenting the contents of 
a database.21 That investment must be substantial in a quantitative and qualitative 
sense, and cannot be in the creation of the data but is rather in its collection into 
the database.22 Employees are excluded from the right unless their inclusion is 
specified by contract.23  The right can be held jointly and by many people. It 
protects against substantial extraction or reutilization of all or a substantial part of 
the database without consent.24 The term of the database right is 15 years from 
the date when the database was completed, but any substantial change to the 
contents of a database qualifies the resulting database for its own term of 
protection.25 The database right also allows a right of fair dealing with the 
database for research for non-commercial purposes. 
In the following section we describe our analysis of the eDiaMoND project, 
the ways in which these laws impact upon the collaborations within the project 





Analysis of eDiaMoND 
Methodological approach 
The IMaGE project was a 1 year collaboration between lawyers, social 
scientists and software engineers. This consortium of researchers came together 
in order to understand and evaluate current IP law and social practice. In addition, 
we sought to develop recommendations for policy regarding alternative ways in 
which the law might operate in the future. As stated previously, in order to 
understand how these issues emerged in practice, we conducted a retrospective 
study of the eDiaMoND project. By surveying the applicable IP laws, our analysis 
attempted to determine where, and in what artefacts of eDiaMoND, IP could be 
seen to reside. And more importantly, who, for the purposes of the law, should own 
the IP? These legal findings were then applied to the actual practices from the 
case study to uncover who ‘in reality’ owned and controlled the IP in eDiaMoND. As 
our findings indicate, who owned the IP in practice did not mirror who legally 
owned the IP. We also identified potential difficulties with the contractual 
arrangements of the project. 
Our methodological approach evolved in three phases. In the first phase, 
we conducted a retrospective study of the eDiaMoND project by analyzing 
documents produced by the project combined with unstructured interviews with 
key members of the eDiaMoND team and its stakeholders. These materials 
provided the background to the project and its aims; a sense of the challenges 
that members of the project faced; and a catalogue of the agreements that were 
 
 
reached during the project between its partners. In parallel, a thorough review of 
relevant jurisprudential research relating to the ownership (IP) rights was 
conducted.26 The second phase focused on the development and evaluation of 
various models for the ownership of IP rights in such data. The final phase 
disseminated our findings, after which we re-evaluated our models from the 
feedback. In addition, the IMaGE team analysed the viability of technical controls 
that complemented methods of legal regulation, e.g. technology protection 
measures (TPMs) that could be employed as a means of digital rights management 
(DRM) to ensure that IPRs in digitized mammograms are preserved and controlled 
in compliance with the law. Space prohibits a thorough description of this 
research in this article, but see [19]. 
 
eDiaMoND practices around data acquisition and contractual 
agreements 
In order to fulfil the aims and objectives of the project, the eDiaMoND 
consortium acquired some 1600 digital mammograms and patient-related 
information from four clinics. As IP was central to the negotiations of the 
collaborators involved, our analysis focused on the process of data acquisition 
and the agreements that were forged to facilitate it. Once ethical clearance 
had been given, the necessary images and patient-related data information were 
obtained from clinics via a university intermediary who then liaised with Oxford to 
upload the data into the project’s database. The commercial partners provided the 
technology to acquire data and place the data in standardized form on the grid. 
 
 
The mammograms used included those already pre-selected for training or 
epidemiological purposes in addition to those taken directly from patients in the 
clinic. The majority of mammograms were film-based X-rays. Patient records 
were generally on paper. Thus, much of the effort of acquisition was expended on 
the scanning and data entry that was necessary to digitize the data. However, a 
number of cases were taken directly from digital equipment. This complex process 
of data collection and use is critical in considering the IP rights involved. 
As a result of the numerous participants, the sensitive data and the 
technology implicated, the parties concluded agreements to manage the 
expectations and interests of the various clinical, research and commercial interests 
in the IP of the images involved. More often than not, agreements were made 
orally, rather than in writing. In some cases, no explicit allocation of IPRs was 
discussed or reached. The project partners exhibited significant uncertainty as to 
‘who owned what images’ at the end of the project. At the top level, eDiaMoND 
was based on a three-way collaboration agreement between Oxford and the 
two major commercial partners. This agreement clarified, for example, what 
would happen to any IP that was developed in the form of software during the 
project. However, it made no mention of medical data. The data were to come 
from the participating clinics. Each of these clinics, in collaboration with their 
individual university partner, was to acquire data and upload them into the 
project’s grid database. Unlike the main collaboration agreement, the 
relationships between each participating university and their clinic, and between 
those universities and Oxford, were ad hoc, and in some cases quite informal. As 
 
 
the following will describe, this makes ownership of those data much harder to 
define. 
 
eDiaMoND ownership rights 
Ownership rights among trusts and universities. The IMaGE project 
examined the ownership right in MMRs as artistic works and the data and 
software as literary works. An individual MMR may have three types of copyright 
attached: copyright in the actual image, copyright in the annotations, and copyright 
in the entire record. Copyright is also vested in eDiaMoND’s entire database of 
mammogram data, whether textual or in image form. Copyright ownership in 
each may vary depending on the general rules of copyright.27 
In eDiaMoND, the trusts have been found to retain copyright over the 
original images and possibly the digitized images. This ownership has been vested 
in two different ways: 
(1) by express agreement and (2) by implied licence. The first case of 
express agreement was less common: only in one trust–university relationship 
(Clinic 1 and University 1, respectively) was IP ownership specified. A clause in the 
agreement clearly specified that the data be retained by Clinic 1 with University 1 
enjoying use rights for the eDiaMoND project only.28 In the case of the other three 
trust–university relationships there was an implied licence between the parties, 
based on the absence of a written contract and the exchange of communications 
between the parties. As independent contractors, the trusts retain the data because 
they are the creators of the data. So despite the lack of a contract, ownership rights 
 
 
can still be implied. Even so, the exact scope of this licence is unclear (e.g. whether 
the data can be used for commercial purposes or for other non-commercial 
purposes). Going forward with more certainty in ascribing ownership rights is 
necessary. 
 
Ownership rights among radiographers and others. Most of the 
radiographers or technicians who scanned and/or annotated the images were 
employees of the trusts. As such, all IP generated by them belongs to the trusts due 
to the absence of a formal contractual agreement. However, several technicians were 
not employees but independent contractors; such status raised ownership concerns. 
For instance, in the relationship between Clinic 1 and University 1, despite the 
contractual certainty in the flow of IP rights among these entities, the work of an 
independent clinical assistant who scanned images supplied by Clinic 1 and 
entered data from clinical records for University 1 raised ambiguity. The clinical 
assistant was paid by University 1 but worked at Clinic 1, and although she was 
bound by an honorary contract with the clinic, the contract made no explicit 
mention of IPRs.29 The data generated can therefore be owned either by the 
assistant as an independent contractor or by the university. This would be a 
perverse result for the future of such a project as eDiaMoND, as the expectation 
among the parties, and the NHS, is that the data are to be retained by the trust.30 
Uncertainty in these rights could result in an incomplete database. Any future use 
of the eDiaMoND data generated by the radiographer and the IP in such data 
would require permission (and it is uncertain who would be in a position to 
 
 
authorize this use). 
The eDiaMoND project used a number of independent contractors, 
particularly for data acquisition. However, there are also potential concerns relating 
to permanent employees. Consider the case of a research assistant at University 
2 who obtained digitized images from Clinic 2, and then entered various pieces of 
patient data. According to NHS policy,31 when medical research and development 
are conducted in partnership with industry or universities, the partners should, 
where possible, agree IP arrangements in advance. The fact that this was not done 
makes it likely that the data in this case are owned either by the research associate, 
or by University 2, another perverse conclusion. The important assumption here is 
that these workers (the research assistant, the radiographer, or the clinical 
assistant) did create original works to attract copyright protection.32 In the case of 
the radiographer, a case for copyright protection is more easily made because 
of her exercise of skill and judgement, though arguably the same holds for the 
others who acted similarly.33 
 
Ownership rights in software. Software ownership does not raise any 
major concerns as Oxford and the participating software companies had 
concluded a collaboration agreement. The companies jointly own any software 
developed for eDiaMoND. Oxford has a perpetual non-exclusive licence to use 
software for non-commercial purposes. This may become problematic should 
Oxford decide to use the same software application for commercial purposes. 
Similarly, the software companies may not necessarily enjoy the rights to use the 
 
 
MMR data to train and test implementations. 
Copyright in databases 
Databases are protected by copyright if they are the author’s ‘own 
intellectual creation’.34 The creativity required for protection is in the selection 
and/or arrangement of the contents of the database.35 Copyright protection of 
the database requires a relatively high standard of originality. The author holds 
the right and it protects rights of reproduction, distribution and making available 
to the public. 
Whilst the issue of whether the various databases in general qualify as a 
‘literary work’ remains an open question, we can draw preliminary conclusions 
about copyright that may be held by various project stakeholders. Clinic 1 and Clinic 
3 both contributed pre-existing local databases to the eDiaMoND project. They had 
already selected various typical images for teaching purposes and had arranged 
those images according to their internal filing system. These databases would 
likely meet the threshold for copyright protection. The other clinics assembled 
their local databases by choosing patients in the waiting room who consented to 
the use of their images for the purposes of eDiaMoND. This level of selection and 
arrangement less convincingly meets the threshold for copyright protection. The 
eDiaMoND project, in the creation of a database incorporating the databases of 
the participating trusts, delegated selection of database elements to the local trusts. 
eDiaMoND coordinated the scanning, sorting of information fields and overall 
layout of the data in the database and would, thus, meet the standard of 
‘arrangement’. Consequently, the larger database as well as some of the 
 
 
participant databases would likely be subject to both eDiaMoND and participant 
claims to copyright over the databases. 
 
Conclusion on copyright ownership 
The trusts own the IP in the original images and likely in the digital 
images. This results from an implied licence or, in the case of Clinic 1, through an 
explicit licence in the form of a contract. Both approaches provided the same 
short-term results. The universities were able to use the data for the eDiaMoND 
project, and the trusts, in turn, expected to retain the rights to the data. However, 
in the longer term, more legal certainty is necessary for the success of e-science and 
the vision of sharing and reuse of medical data in general. This uncertainty 
becomes pressing particularly when considering independent contractors who 
may have ownership rights in the data generated. NHS policy, which arguably 
mandates that ownership of medical data is vested in the trust, would not 
support such a result. Lastly, eDiaMoND project participants collectively retain 
use rights in the images for the duration of the programme but do not have reuse 
rights from either an IP or an ethical clearance perspective. Even if ethical 
clearance was granted for a follow-on piece of research, a lack of IP clarity could 
lead to undesirable consequences. This concern applies not only to the eDiaMoND 
project specifically, but also to e-science projects more generally. 
 
Conclusion on database ownership 
 
 
The parties involved in the eDiaMoND project did not turn their attention to 
the ownership of databases when they were planning the project. This is evident 
from the documentary and interview research conducted. This means that the 
state of IP held in the databases is uncertain and has stalled future sharing and 
further technical exploitation of the existing databases. Some trusts have a 
strong claim to copyright and database rights in their databases due to their 
pre-existing collection activities. The creators of the eDiaMoND database are also 
likely to have copyright and database rights in the databases of mammogram 
images. It is interesting to note that the database right is not well tailored to 
the case of a mixed public and privately funded initiative. The database right in 
this case also highlights the intersection between the originality requirement 
for copyright and the legal criteria of the database right. 
 
The eDiaMoND database and database rights 
The eDiaMoND collection, as well as some of the pre-existing 
databases held by the trusts, fall under the legal definition of database.36 They are 
collections of images that are separable from one another without affecting their 
value and have been systematically or methodically arranged to be independently 
accessible from a fixed hardcopy or electronic base.37 In the eDiaMoND project, 
clinics 1 and 3 took particular efforts to create their pre-existing collections by 
selecting representative MMRs, verifying the accuracy of the MMRs and their use 
as typical cases, and presenting them in the database according to their internal 
filing system. Clinics 2 and 4, however, have a weaker claim to database 
 
 
protection over their pre-existing collections since those collections were largely 
incidental to the creation of data, as discussed previously. Thus, some of the trusts 
have a stronger claim to rights in their databases than others. In terms of the larger 
eDiaMoND database, a range of organizations took the initiative and assumed the 
risk in investing in and obtaining data in database form, through coordinating 
standardized annotation and scanning, as well as verifying and presenting the 
contents of the database. In particular, a global computer firm, Engineering and 
Physical Sciences Research Council (EPSRC), the Department for Business, 
Enterprise and Regulatory Reform (formerly the DTI) and the Medical Research 
Council (MRC) made the most financially significant investments, although 
questions may remain over the threshold for finding ‘substantial investment’.38 The 
core eDiaMoND team at the University of Oxford and its commercial spin-out 
partner undertook the most substantial investment and initiative in obtaining and 
verifying data. The legitimate claims to eDiaMoND by commercial and government 
partners over a database of sensitive medical information highlights an area of 
potential legal and ethical conflict. 
 
General conclusions 
Our research concludes that trusts likely own and control the IP in MMRs 
in these types of large-scale collaborative projects in the medical sector. This 
arrangement should be clarified at the onset by explicit agreement; additional 
concerns relating to patient confidentiality and ownership of their data must also be 
addressed. A legally clear situation may be preferable to one where the legal rights 
 
 
are determined ad hoc, after the fact, or during a formal legal dispute. Once ethical 
considerations have been satisfied, without a clear notion of IP ownership it is 
impossible to know who has the authority to approve new research, or indeed 
who should benefit from any subsequent commercial  exploitation. These questions 
hold the potential to severely challenge the concept of seamless data sharing that is 
so critical to the e-science vision and the integrated health record. 
 
 
Governance of IP ownership 
A key objective of the IMaGE project was to develop 
and then assess models that managed the ownership of 
IPRs associated with collaborative databases of medical 
images and associated textual data. It was hoped that such 
models of IP would provide more clarity for future e-health 
initiatives such as the IHR, and stimulate debate as to how 
IP should govern ownership of digitized medical data. Based 
on the findings from our investigations, we examined three 
distinct conceptual models of potential IP governance of 
digitized medical data for secondary uses: (1) NHS trust 
centred, (2) patient centred, and (3) a national ownership 
model. Trust governance 
 
 
Our research suggested that the most common expectation amongst 
the parties was that the IP in a patient record was vested in the trust from 
whom the patient received treatment or a diagnosis, subject to a patient’s limited 
control over the data. The scope of the patient’s control would be defined mainly 
through the patient’s statutory rights in her medical records. This model therefore 
recommends maintaining the status quo of trusts retaining local control and 
responsibility for protecting data as deemed owner of the IP. However, the situation 
would be clarified by a policy document for all trusts specifying the permitted uses 
of the IP in the data. Under this model the trusts would remain one of the 
beneficiaries of any databases created using their data. Further, standard clauses 
would be developed allowing, for example, non-exclusive rights in other trusts to 
access the data for research, diagnosis and treatment purposes and granting the 
NHS a worldwide, irrevocable, royalty-free licence for its own non-commercial 
purposes. Researchers would negotiate with each individual trust to obtain the 
required set of data as is currently done. However, more ambitious variation would 
see trusts adopt an open access approach, implemented through creative 
commons or public licence type contracts. 
 
Patient-centred  governance 
A radically different model would allow patients to own the IP in their 
medical record. Currently, while patients have statutory rights to access and control 
uses of their data, they do not hold any copyright or database rights in their 
records. Contracts between all parties could be standardized to assign all IP to the 
 
 
patients. Similarly, legislative amendments could vest all IP in the context of medical 
data to patients. As in the music industry, a collecting organization could be 
established to manage patients’ new rights and act as a conduit. Patients could 
then receive royalties based on the uses of their data. Patients could opt to waive 
their rights to remuneration in all cases or in some (e.g. collect money for commercial 
uses of data), or manage them through ‘open source’ licensing arrangements (as 
discussed above). Through compulsory licensing, patients could be obliged to 
license their data. A tribunal could set tariff amounts and resolve any disputes. 
 
National governance 
The third model proposes to assign IP rights in the medical record 
to a central organization (or, for example, to the Secretary of State for 
Health). This would be similar to the kind of national database proposed 
by ‘Connecting for Health’. Medical records could be created as the 
result of clinicians’ work at multiple NHS trusts, researchers might draw 
on records originating all over the country, and the exploitation of these 
records could then be handled by a single national body. In cases where 
clinicians have established their own collections of records for research 
or training purposes, the exploitation of such collections can be 
protected by the database right. It may be possible to implement this 
model using contracts; however, a more compelling alternative would be 
 
 
legislative reform, where for example a sui generis law on medical data 
in research collaborations could vest ownership in a national body. 
Alternatively, legislation could be enacted to provide a limited exception 
to infringement in the UK Copyright, Designs and Patents Act 1988 (e.g. 
in the form of fair dealing or for use of the work for purely educational 
or research purposes).  
Analysis of the governance models 
Our approach to and conclusions about the evaluation of these models 
combines our own understandings of existing policies, for example of IP in the 
NHS, and consultation with a wider group39 at workshops we hosted and attended. 
The first model best serves the needs of e-health collaborators in the 
short term as it supports and clarifies the current system of trust that exists 
among researchers, without significantly changing the way the research community 
currently  views  IP  ownership.  It does not require legislative change, and it co-
locates data and IP control in the trusts. Disadvantages are that it could 
undesirably relegate responsibilities to inexperienced administrators and 
researchers and ineffectively address the fragmentation of approaches across 
projects and regions. The first model’s approach would not be successful if standard 
clauses are not developed and used by collaborators to make the rights allocations 
abundantly clear at the point at which a project is initiated. 
The second model allows collection of and access to vast quantities of data 
whilst patients retain IP ownership interests. Incidentally, this model could provide 
 
 
accountability to patients for use of their data. However, granting patients 
ownership rights may be problematic as it: (1) runs contrary to the default state of 
the law; (2) may make it more difficult to establish research projects with commercial 
partners; (3) is highly ambitious and may be cumbersome to implement; and most 
importantly, (4) runs contrary to NHS policy on the exploitation of IP. Indeed, the 
very idea of patients potentially making money from their data in a public 
healthcare system seems undesirable. Additionally, some patients have suggested 
that ownership is not needed provided there remain sufficient safeguards in the law 
to regulate the use and dissemination of such data, and in particular to ensure 
that the data remain sufficiently anonymized. 
The main disadvantage of the third model is that although legislative 
reform may be more effective and result in a larger data repository, especially in the 
longer term, legislative reform is time-consuming and difficult to attain. 




This analysis of the ways in which contractual arrangements were 
forged within the eDiaMoND project, coupled with our understanding of the 
practices of data acquisition and the current state of IP law, have enabled the 
project to make some specific recommendations for future research into the 
sharing of medical data in such projects and data reuse. For example, 
independent contractors were employed to work on the data collection, 
 
 
primarily to scan and/or annotate images. This resulted in some uncertainty and 
thus potential problems for the trusts as to where the IP may lie. If not explicitly 
expressed, a default position may result in copyright residing with the 
independent contractor. This would suggest that honorary contracts should 
be more specific and include IP arrangements. Such contracts could, and 
arguably should, include clauses clarifying that the trusts retain copyright in the 
independent contractor’s works on behalf of the trust. Such an approach may 
encourage researchers at universities and clinics to consider the data used and 
generated as valuable assets that are best exploited with clear contractual 
provisions regarding ownership of the IP. In terms of the governance models it seems 
that the trust governance model is the most feasible to implement in the short term. 
This readily serves the needs of the rapidly developing e-health systems, many of 
which are currently affected by the lack of clarity and guidance. However, it is also 
crucial that the NHS, working with the medical and research communities, raise 
awareness on the importance of IP, evaluate the potential of standardizing IP clauses, 
and address basic technological measures that must be implemented in order to 
support the model. This is a timely opportunity as the National Programme for IT 
(NPfIT) is being deployed across England. A slightly modified version may designate 
regional hubs to allow small variations to be enacted to suit local needs. However, a 
longer-term and a more permanent solution would be to move towards national 
governance. But this would, as noted, necessitate time-consuming legislative 
reforms requiring further research into IP, consultation with the research 
community and open debates involving the public at large. 
 
 
Electronic health records will allow individuals to share medical data 
across numerous organizations in increasingly dispersed geographical  locations.  This  
continues  to  raise new copyright and data protection challenges. Greater 
certainty in this rapidly changing landscape is crucial for the ongoing success of  
pioneering  projects  like  eDiaMoND. Good governance of SUS will be critical  for  
future  e-health  systems.  Additionally,  we need to understand the interplay 
between IP and ethical issues as well privacy, property, confidentiality and consent 
in order to enable advances and innovations in the medical field that may 
ultimately improve healthcare. 
 
Notes 
1 This research was supported by the ESRC as part of the e-Society Programme project 
entitled ‘IMaGE 
– Intellectual Property Rights in Medical Databases for a Grid Environment’, under grant 
number ESRC RES-341-25-0033,  2005–6. 
2 Note that the IMaGE project does not focus on physical ownership issues (e.g. which 
entity is best able to store the physical boxes of data); the focus is on the intangible aspect of such 
property, the IP. 
3 Copyright, Designs and Patents Act 1988 c. 48 as amended. 
4 CDPA s. 2 (1) exploitation rights delineated further in Part II. For comparative 
purposes to Canada’s Copyright Act RSC 1985 c. C-42 (‘CCA’) s. 3, copyright means the sole right 
to reproduce, perform or publish a work and procure any profits therefrom. 
5 University of London Press Ltd v. University Tutorial Press Ltd [1916] 2 Ch 601, 608: 
‘the Act does not require that the expression must be in an original or novel form, but that the 
work must not  be copied from another work – that it should originate from the author’. Or as J. 
Litman The Public 
Domain (1990) 39 Emory L. J. 965–1023, 1000 states, originality is used for dividing 
works ‘privatelyowned from the commons and to draw lines among the various parcels of private 
ownership’. 
There are various views on the subject that elide clear definitions. 
6 W. R. Cornish Intellectual Property (5th edn Sweet & Maxwell London 2003) 388; 
CCH v Law Society of Upper Canada [2004] 1 SCR 339: ‘What is required to attract copyright 
protection in the 
expression of an idea is an exercise of skill and judgment.’ See also Slumber-Magic 
Adjustable Bed Co v Sleep-King Adjustable Bed Co and others [1984] 3 CPR (3d) 81 (BCSC). 
7 W. R. Cornish Intellectual Property (5th edn Sweet & Maxwell London 2003) 388; 
Ladbroke (Football) Ltd v William Hill (Football) Ltd [1964] 1 All ER 465 (HL). 
8 M. Woodmansee ‘The Genius and the Copyright: Economic and Legal Conditions of 
the Emergence of the “Author”’. Eighteenth-Century Studies 425–48, 426. 
9 CDPA s. 11 (2); in Canada, Copyright Act RSC 1985 c. C-42 s. 13 (3); in the US, 
 
 
Copyright Act 1976 17 USC s. 101 ‘works made for hire’. 
The distinction between licences and assignments ‘is not always so clear-cut’; an 
exclusive licence  of all rights to run until the rights expire is in practical effect like an assignment. 
And so, ‘it is not so  
much what the contract is called but the effect of the transaction which decides whether 
there is an assignment or a licence’. H. Pearson and C. Miller Commercial Exploitation of 
Intellectual Property (Blackstone Press, London 1990) 344. 
11 CDPA s. 92 (1). 
12 D. Vaver Copyright Law (Irwin Law, Toronto 2000) 238. 
13 Pearson and Miller (n. 14) 343. 
14 CDPA s. 91. 
15 CDPA ss 94–95. 
16 Directive 96/9/EC of the European Parliament and the Council of 11 March 
1996 on the legal protection of databases. 
17 Copyright and Rights in Databases Regulations 1997 (SI 1997 no. 3032). 
18 Reg. 6. 
19 Fixtures Marketing Ltd v. Organismos Prognostikon Agonon Podosfairon AE 
(OPAP) [2004] ECR I-10549. 
20 Fixtures Marketing v. Svenska AB C-338/02; OPAP (n. 39); Fixtures Marketing 
Ltd. v. Oy Veikkaus Ab 
C-46/02; British Horseracing Board Ltd v. William Hill Organization Ltd C-203/02 (BHB). 
21 Reg. 14 (1). 
22 BHB (n. 42). 
23 Reg. 14 (2). 
24 Reg. 16 (1). 
25 Reg. 17 (3). 
26 Note that it was beyond the remit of the IMaGE project to address conflicts 
between individual rights and collective demands, as these are resolved through confidentiality, 
privacy and data protection  law. The IMaGE project instead focused on the intellectual property 
legal regime and the behaviour in practise of the stakeholders in such regime as it applies to shared 
medical data. 
27 Despite these differences, copyright persists for 70 years from the time of first 
fixation. 
28 All IP arising from the performance of the work by [Clinic 1] for the purpose 
of the eDiaMoND project shall remain vested in [Clinic 1]. [University 1] shall procure that [Clinic 1] 
shall grant a licence to [University 1] and [University 1] shall grant a paid up licence to Oxford so 
that each of [University 1] and Oxford shall have the right to use the mammograms (including any 
adaptation thereof), and other data for the purposes of the eDiaMoND project (which for the 
avoidance of doubt shall include a right to make the same available to any other eDiaMoND project 
participant for such purpose only). 
29 The actual contract was not available to us; however similar honorary 
contracts from this NHS trust make no mention of IP. 
30 See Department of Health, ‘NHS Framework and Guidance on the 
Management of IP in the NHS’, 
http://www.innovations.nhs.uk/pdfs/77169_doh_nhsnnovative_orgfinal.pdf>, UK, September 2002 
(took effect 9 September 2002 along with Health and Social Care Act 2001). 
31 Ibid. 67–9. 
32 The mere mechanical act of transforming a work from analogue to digital 
format may not constitute an original work and may in fact attract copyright infringement; see in 
the US Tasini v New York Times 533 US 483, 121 S Ct 2381 (2001). 
33 For example, even what initially seemed like straightforward data entry 
required some skill, requiring the assistant to rearrange a given set of clinical data fields so that 
 
 
they may be entered into the ‘unified’ scheme required by the eDiaMoND database. Thus it was 
important so that the assistant was able to read and understand the clinic’s original medical 
records. 
34 Database Directive, Article 3. 
35 Article 3 (1). 
36 Note that the database right does not protect the computer software driving 
the database: Article 1 (3). Computer programs are protected independently by the European 
Software Directive of 1991: Council Directive 91/250 on the legal protection of computer 
programs, OJ L 122/42 of 17 May 1991. 
37 Ibid. nn 29–36. 
38 Due to space constraints only an overview of the contributions is provided. 
 
This group comprised a range of stakeholders including those from the NHS, medical law 
practitioners, technology developers and researchers, medical researchers and patents advisers.  
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